Roche’s hostile takeover bid for next-generation gene sequencing powerhouse Illumina is aimed not merely at growing its diagnostics business but at accelerating the move of whole-genome sequencing from research to clinical use, according to the company.
“There’s clearly a gap today and that is the ability for sequencing to be used in routine in-vitro diagnostics,” said...